High False-Positive Rate of (1, 3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies. (6th January 2022)

• Record Type: Journal Article
• Authors: Tschopp, Jonathan; Brunel, Anne Sophie; Spertini, Olivier; Croxatto, Anthony; Lamoth, Frederic; Bochud, Pierre Yves
• Is Part Of: Clinical infectious diseases. Volume 75:Number 2(2022)
• Page Start: 330
• Page End: 333
• Publication Date: 2022-01-06
• Subjects: β-D-glucan -- intravenous immunoglobulines -- therapeutic antibodies -- false-positive -- onco-hematology; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab1028
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1, 3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.